MetaCap

Cardiol Therapeutics (CRDL) vs enGene Therapeutics (ENGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed enGene Therapeutics (ENGN) over the past year, losing 11.3% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $110.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%ENGN-75.00%
+146%+28%-90%
Nov 21, 20251 yearNov 20, 2026
CRDL-52.34%ENGN-82.35%
+202%+52%-98%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus ENGN key metrics
MetricCRDLENGN
Share price$0.8626$1.74
Market cap$110.14M$116.61M
1-day change-2.28%-1.14%
YTD return-9.58%-80.73%
1-year return-11.35%-75.00%
5-year return-60.06%—
EPS (TTM)$-0.24$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-117.30M
52-week high$2.34$12.25
52-week low$0.8417$1.40
Distance from 52-week high-63.14%-85.80%
Analyst consensusstrong_buybuy
Avg. price target upside+874.96%+146.55%
Average volume1.20M1.12M
Shares outstanding127.69M67.02M
Employees1881
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed ENGN by 63.7 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

CRDL vs ENGN FAQ

Which is bigger, Cardiol Therapeutics or enGene Therapeutics?

enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $110.14M for Cardiol Therapeutics (CRDL).

Which stock has performed better over the past year, CRDL or ENGN?

CRDL returned -11.35% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and enGene Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons